MG
Therapeutic Areas
Korro Bio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| KRRO-121 | Urea Cycle Disorders / Hepatic Encephalopathy | Preclinical |
| GalNAc Program | Alpha-1 Antitrypsin Deficiency (AATD) | Preclinical |
| AMPKγ1 / Longevity (Liver) | Metabolic/Liver Disease | Discovery |
| CNS Program | Amyotrophic Lateral Sclerosis (ALS) | Discovery |
Leadership Team at Korro Bio
RA
Ram Aiyar
Chief Executive Officer & President
LV
Loic Vincent
Chief Scientific Officer
NG
Noel G. McElvaney
Clinical Advisory Board
PS
Pavel Strnad
Clinical Advisory Board
JT
Jeffrey Teckman
Clinical Advisory Board
AM
Alice M. Turner
Clinical Advisory Board
TC
Todd Chappell
Chief Operating Officer
JM
Jeffrey M. Cerio
SVP, General Counsel
SE
Stephanie Engels
Chief People Officer
GZ
Gaozhong Zhu
SVP, CMC & Technical Operations